Diabetic gastroenteropathy : An underdiagnosed complication
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved..
This article is an extensive review that provides an update on the pathophysiology, symptoms, diagnosis, and treatment of diabetic gastroenteropathy. There is no reported prevalence, but it has been described that patients with type 1 diabetes have a cumulative incidence at 10 years of 5.2%, and type 2 patients, 1%. Also, in the group of type 1 diabetes, it has been observed that women are more likely to present this condition (5.8% vs 3.5%). Many factors are associate with its development (e.g., hyperglycemia, vagal dysfunction, loss of expression of neural nitric oxide synthase in the myenteric plexus, alterations in the Cajal interstitial cell network, and oxidative stress). Gastrointestinal discomfort could be perceived 70% higher in diabetic patients, describing that 25% of diabetic patients experience gastrointestinal symptoms. Diabetic enteropathy could affect any portion of the gastrointestinal tract, but esophageal alterations were described in more than 60% of diabetic patients, also 60% of them present constipation, and 20%, diarrhea. Gastric emptying scintigraphy is useful to evaluate gastroparesis, therefore, gastric retention of more than 60% at 2 h has a sensitivity of 100% and specificity of 20% for diagnosis; however, other studies such as breath tests, with a sensitivity of 89% and a specificity of 80%, or the endoscopic capsule contribute to the diagnosis. There is no cure; however, management must be multidisciplinary, focused on slowing the progression of diabetic gastroenteropathy, reducing symptoms, and restoring function; that includes nutritional recommendation, maintain glucose levels kept below 180 mg/dL, use of prokinetics, anti-emetics; nowadays, it has been special interest in surgical treatment, such as pyloroplasty, also gastric electrical stimulation appears to be another alternative.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
World journal of diabetes - 12(2021), 6 vom: 15. Juni, Seite 794-809 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Concepción Zavaleta, Marcio José [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Complication |
|---|
| Anmerkungen: |
Date Revised 26.06.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4239/wjd.v12.i6.794 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327158824 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327158824 | ||
| 003 | DE-627 | ||
| 005 | 20231225200145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4239/wjd.v12.i6.794 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327158824 | ||
| 035 | |a (NLM)34168729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Concepción Zavaleta, Marcio José |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetic gastroenteropathy |b An underdiagnosed complication |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a This article is an extensive review that provides an update on the pathophysiology, symptoms, diagnosis, and treatment of diabetic gastroenteropathy. There is no reported prevalence, but it has been described that patients with type 1 diabetes have a cumulative incidence at 10 years of 5.2%, and type 2 patients, 1%. Also, in the group of type 1 diabetes, it has been observed that women are more likely to present this condition (5.8% vs 3.5%). Many factors are associate with its development (e.g., hyperglycemia, vagal dysfunction, loss of expression of neural nitric oxide synthase in the myenteric plexus, alterations in the Cajal interstitial cell network, and oxidative stress). Gastrointestinal discomfort could be perceived 70% higher in diabetic patients, describing that 25% of diabetic patients experience gastrointestinal symptoms. Diabetic enteropathy could affect any portion of the gastrointestinal tract, but esophageal alterations were described in more than 60% of diabetic patients, also 60% of them present constipation, and 20%, diarrhea. Gastric emptying scintigraphy is useful to evaluate gastroparesis, therefore, gastric retention of more than 60% at 2 h has a sensitivity of 100% and specificity of 20% for diagnosis; however, other studies such as breath tests, with a sensitivity of 89% and a specificity of 80%, or the endoscopic capsule contribute to the diagnosis. There is no cure; however, management must be multidisciplinary, focused on slowing the progression of diabetic gastroenteropathy, reducing symptoms, and restoring function; that includes nutritional recommendation, maintain glucose levels kept below 180 mg/dL, use of prokinetics, anti-emetics; nowadays, it has been special interest in surgical treatment, such as pyloroplasty, also gastric electrical stimulation appears to be another alternative | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Complication | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Gastroenteropathy | |
| 650 | 4 | |a Gastrointestinal disease | |
| 650 | 4 | |a Gastroparesis | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Gonzáles Yovera, Jhean Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Marreros, Diego Martín |e verfasserin |4 aut | |
| 700 | 1 | |a Rafael Robles, Luciana Del Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Palomino Taype, Kely Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Soto Gálvez, Karen Nohelly |e verfasserin |4 aut | |
| 700 | 1 | |a Arriola Torres, Luis Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Coronado Arroyo, Julia Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Concepción Urteaga, Luis Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of diabetes |d 2010 |g 12(2021), 6 vom: 15. Juni, Seite 794-809 |w (DE-627)NLM207896593 |x 1948-9358 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:6 |g day:15 |g month:06 |g pages:794-809 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4239/wjd.v12.i6.794 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 6 |b 15 |c 06 |h 794-809 | ||